Bronchiolitis Obliterans Syndrome (BOS) Recruiting Phase 2 Trials for Belumosudil (DB16703)

Also known as: Obliterative Bronchiolitis / Bronchiolitis Obliterans / Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans Syndrome / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05922761BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)Treatment